The State of AI in Pharmaceutical Drug Development

This Forbes article was written following a lecture Dr. Niven R. Narain, Ph.D., BERG Co-Founder, President and CEO, gave at Harvard Medical School during the AI Applications Summit for BioPharma in October.

 

The conference provided a useful snapshot into what is happening at the intersection of AI and life sciences and the article describes the author’s ten key observations.

 

To read the full article, click here

Berg Analytics to Present at the AMIA 2018 Annual Symposium

Nov 02, 2018, 07:04 ET


BOSTONNov. 2, 2018 /PRNewswire/ — Berg Analytics, a division of BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the acceptance of a poster for presentation describing data-driven predictive modeling for septic shock at the American Medical Informatics Association (AMIA) 2018 Annual Symposium being held November 3-7, 2018 in San Francisco.

“Sepsis and septic shock are life threatening conditions. The onset of septic shock is often unpredictable and can lead to emergency hospitalization. We are thrilled to present the results of a data-driven and population-wide analysis by the Berg Analytics artificial intelligence platform, bAIcis,” said Slava Akmaev, Ph.D., Senior Vice President and Chief Analytics Officer of BERG. “The results reveal that a combination of routinely performed lab tests and diagnosis codes can be used to identify at-risk patient populations with a clinically actionable positive predictive value at 24 hours before onset. This predictive model can be used at the point-of-care to advance the diagnosis and management of this tremendously challenging condition.”

In this study, Berg Analytics has employed publicly available intensive care unit stay data to build a novel predictive model for septic shock through use of bAIcis®, Berg Analytics’ proprietary artificial intelligence-based analytics program that infers Bayesian models from data to produce networks containing cause-and-effect relationships. Further validation of this model could address the unmet need of a reliable decision support system for clinicians to identify patients at high-risk of advancing into septic shock early for a meaningful intervention.

“We are on the cusp of major breakthroughs in the application of artificial intelligence, machine learning, and computational science, which carry the potential to dramatically improve the quality and affordability of healthcare globally,” said Niven R. Narain, Ph.D., BERG Co-Founder, President and Chief Executive Officer. “The results presented serve as a proof-of-concept paving the way for BERG to validate these models and advance similar activities within other health conditions to help clinicians proactively manage patient care.”

Details of the poster presentation are as follows:

Title: Data-Driven Discovery of Models for Predicting Septic Shock in the Intensive Care Unit
Presenter: Vijetha Vemulapalli, Director, Digital Health Analytics, BERG
Date and TimeNovember 5, 2018, Poster Session 1: 5:00 – 6:30 P.M. PT 
Poster Number: 2971684

About BERG
BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimed at the most promising therapeutic targets and pathways. BERG has leveraged both Interrogative Biology and traditional R&D methods to develop a robust pipeline of first-in-class product candidates and diagnostics that advance bold innovations that have the potential to improve patient lives. To learn more about how we’re enabling bold innovation, visit berghealth.com.

Media Contact:
Chris Dougherty
Ogilvy
917-515-9876
BERG@Ogilvy.com

BERG Investor Contact: 
Molly Cameron 
BERG 
617-588-1000 
Molly.Cameron@BergHealth.com

SOURCE BERG

Fortune.com: 3 Ways AI Is Changing Healthcare

This Fortune article discussed how BERG is reinventing drug R&D to change healthcare.

For the full article, click here.

Big Data: Is It Crunch Time for Pharma?

With big data and advanced analytics progressing from fad to frontier status, Pharm Exec examines the readiness of the biopharma industry to take advantage of this promise. Can new digital health tools be harnessed to help advance new treatment approaches and aid decision-making?

Read More

AI in Medicine Journal: Berg Analytics Research Paper

Non-obvious correlations to disease management unraveled by Bayesian artificial intelligence analyses of CMS data

Highlights

  • Data-driven Bayesian networks based analysis has been performed on healthcare data
  • Summarized, healthcare provider level data was used for this analysis
  • Novel hypothesis linking diagnosis codes was proposed based on findings from Bayesian networks approach
  • Potential mechanisms were explored to explain the novel hypothesis
  •  This paper demonstrates the ability of artificial intelligence methods to advance medical research

Read More

CEO Niven Narain Discusses AI, AstraZeneca Partnership on BBC’s “Talking Business”

BBC “Talking Business” Host Aaron Heslehurst interviews BERG CEO Niven Narain. In addition to discussing how artificial intelligence can improve the drug-development process, Narain talks about BERG’s new collaboration with AstraZeneca.

Wall Street Journal: How AI Is Transforming Drug Creation

The Wall Street Journal’s Daniela Hernandez talks to BERG about efforts to advance drug discovery through the use of AI. BERG’s Project Survival is featured as a key example of how we are working to improve the lives of patients through the use of AI technology.

You can read the full article here: http://on.wsj.com/2u7QfmL

Artificial Intelligence: The Way Ahead for Pharma

No longer confined to the realms of science fiction, artificial intelligence (AI) is making its influence felt across many industries, from banking to video games to the food and drink industry.

Here pharmaphorum’s Marco Ricci examines its impact on the pharma and healthcare sectors.

Read more